Protocole, a peptide platform focused on clinical-grade access and personalized protocols, has emerged from stealth with a $6 million seed round led by Rare Capital.
The company is positioning itself at a regulatory inflection point: peptides have gained significant traction across longevity, performance, and metabolic health, but access remains fragmented across research-grade products, compounding pharmacies, and informal networks. As regulatory scrutiny increases and the grey market recedes, access is expected to shift toward regulated pharmacy channels – creating a need for infrastructure that can support safe, scalable, and clinically guided use.
Protocole was co-founded by Delphine Le Grand and Cindy Yan, who worked together in the longevity space and saw demand outpacing the infrastructure required to deliver peptides safely. Through the platform, members complete an intake, receive a personalized protocol based on health goals, and get ongoing access to licensed clinicians, with products fulfilled through regulated pharmacy partners. Rather than offering individual compounds, Protocole structures its offering around goal-oriented protocols supporting areas like recovery, performance, and longevity.
“Peptides are at an inflection point,” said Le Grand. “What Cindy and I saw firsthand was that demand was accelerating far faster than the systems around quality, guidance, and access. As regulation catches up to the category, there’s a need for infrastructure that makes peptides safe, legible, and scalable.”
The company has amassed a waitlist of thousands since its initial launch, with growth driven primarily through word-of-mouth. Funding will support clinical infrastructure expansion, a deeper protocol library, and vertically integrated systems across prescribing, fulfillment, and member experience.
While the platform isn’t women’s health-specific, the peptide category is increasingly relevant to hormonal health, menopause, and longevity for women – and joins a broader wave of companies (including Noom’s acquisition of Tailor Made Compounding and Wisp’s healthy aging expansion) building regulated infrastructure around therapies that have largely existed in unstructured markets.
